Management of myelofibrosis after ruxolitinib failure
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Hematology"
DOI: 10.1007/s00277-020-04002-9
Abstract: Myelofibrosis is a BCR-ABL1–negative myeloproliferative neoplasm characterized by anemia, progressive splenomegaly, extramedullary hematopoiesis, bone marrow fibrosis, constitutional symptoms, leukemic progression, and shortened survival. Constitutive activation of the Janus kinase/signal transducers and activators of transcription (JAK-STAT)… read more here.
Keywords: ruxolitinib failure; fedratinib; ruxolitinib; myelofibrosis ruxolitinib ... See more keywords
Moving beyond ruxolitinib failure in myelofibrosis: evolving strategies for second line therapy
Sign Up to like & getrecommendations! Published in 2023 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2023.2213435
Abstract: ABSTRACT Introduction Ruxolitinib has been the cornerstone of pharmacologic therapy for myelofibrosis for over a decade. However, the last several years have witnessed the regulatory approval of other Janus kinase (JAK) inhibitors for myelofibrosis, i.e.… read more here.
Keywords: moving beyond; myelofibrosis; therapy; ruxolitinib failure ... See more keywords